China has the highest incidence of gastroesophageal cancer in the world. Chemotherapy is the main treatment, although targeted therapies such as trastuzumab (an anti-HER2 MAb for HER2-positive patients), disitamab vedotin (a HER2-directed ADC), ramucirumab and apatinib (VEGFR inhibitors), and PD-1 / PD-L1 inhibitors (as a later-line treatment option) are approved for metastatic disease. In addition, several more targeted therapies (e.g., a VEGFR inhibitor [Chi-Med’s Elunate], a claudin inhibitor [Astellas’s zolbetuximab]), a PD-1/CTLA-4 BsAb [Akeso’s cadonilimab]), and a HER-2/HER-2 BsAb [Zymeworks’ zanidatamab]) are in late-phase development. The launch and continued uptake of the targeted therapies will lead to intense competition and subsequent growth of this therapy market during the forecast period. In this report, we assess how clinical and nonclinical factors—price dynamics, inclusion in the National Reimbursement Drug List (NRDL)—will influence the launch and uptake of targeted therapies for gastroesophageal cancer in China. Understanding the impact of these intersecting factors will be key to the success of current and future players in this burgeoning market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.